Langrehr J M, Murase N, Markus P M, Cai X, Neuhaus P, Schraut W, Simmons R L, Hoffman R A
Department of Surgery, University of Pittsburgh, Pennsylvania 15261.
J Clin Invest. 1992 Aug;90(2):679-83. doi: 10.1172/JCI115911.
The present study was designed to determine whether .N = O produced in vivo during the rejection of histoincompatible tissues might permit serum NO2-/NO3- levels to serve as markers of a rejection reaction. Rat syngeneic and allogeneic liver, heart, bone marrow/spleen cell, small bowel, skin, and sponge matrix grafts were performed and the stable end-products of .N = O, NO2-/NO3-, were serially assayed in the serum of the grafted animals. A significant rise of serum NO2-/NO3- levels in the allografted animals preceded the onset of clinical signs of rejection or graft-versus-host disease, with the exception of the skin and sponge matrix graft models, where elevated serum NO2-/NO3- levels were never observed. In all transplant models, normal serum NO2-/NO3- levels were observed at all times in animals that received syngeneic grafts. Furthermore, treatment of allograft recipients with the immunosuppressive agents FK 506 or cyclosporine A inhibited .N = O production. Determination of serum creatinine levels demonstrated that the elevated serum NO2-/NO3- levels were not caused by kidney dysfunction. Serum NO2-/NO3- levels might be useful early serum markers of the initiation of a rejection reaction or graft-versus-host disease when functional markers of graft dysfunction are not apparent.
本研究旨在确定在组织不相容性组织排斥反应过程中体内产生的.N = O是否会使血清NO2-/NO3-水平成为排斥反应的标志物。进行了大鼠同基因和异基因肝脏、心脏、骨髓/脾细胞、小肠、皮肤及海绵基质移植,并对移植动物血清中.N = O的稳定终产物NO2-/NO3-进行了连续检测。除皮肤和海绵基质移植模型外,在同种异体移植动物中,血清NO2-/NO3-水平在排斥反应或移植物抗宿主病临床症状出现之前显著升高,在皮肤和海绵基质移植模型中未观察到血清NO2-/NO3-水平升高。在所有移植模型中,接受同基因移植的动物血清NO2-/NO3-水平始终正常。此外,用免疫抑制剂FK 506或环孢素A治疗同种异体移植受体可抑制.N = O的产生。血清肌酐水平测定表明,血清NO2-/NO3-水平升高并非由肾功能不全所致。当移植物功能障碍的功能标志物不明显时,血清NO2-/NO3-水平可能是排斥反应或移植物抗宿主病起始的有用早期血清标志物。